A groundbreaking development in kidney transplantation has been unveiled at the Congress of the Spanish Transplant Society (SET) in Bilbao. Biohope, a leading Spanish company in precision medicine, introduced the Immunobiogram® – a revolutionary tool that provides personalized information to adjust immunosuppressive therapy for each patient. This tool aims to minimize the risk of adverse effects such as infections and cancer while maximizing the chances of transplant success.
With over 1.5 million patients living with a kidney transplant worldwide, Spain has been a pioneer in transplant activity, surpassing its best figures in 2023. However, with 50% of transplants lost within a 10-year period, the main cause of graft failure being rejection, the need for personalized medicine in transplantation is crucial.
Dr. Julio Pascual, a leading expert in the field, highlighted the challenge of finding the right balance in medication to ensure successful transplants. The Immunobiogram® provides a unique opportunity for nephrologists to analyze individual responses to immunosuppressants, guiding treatment decisions to avoid rejection and minimize adverse effects.
Isabel Portero, CEO of Biohope, expressed enthusiasm about the potential of the Immunobiogram® to improve clinical outcomes for kidney transplant patients. The tool has already been utilized on over a thousand patients in seven countries and is currently being implemented in reference hospitals in Spain and Portugal.
The introduction of the Immunobiogram® marks a significant advancement in the field of kidney transplantation, offering hope for improved outcomes and a better quality of life for patients with transplanted organs.